EFG Asset Management North America Corp. Has $1.65 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

EFG Asset Management North America Corp. decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 24.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,959 shares of the medical research company’s stock after selling 2,845 shares during the period. EFG Asset Management North America Corp.’s holdings in Charles River Laboratories International were worth $1,653,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at $601,000. JPMorgan Chase & Co. boosted its stake in Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after buying an additional 85,759 shares in the last quarter. State Street Corp boosted its stake in Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after buying an additional 41,421 shares in the last quarter. Janus Henderson Group PLC grew its position in Charles River Laboratories International by 7.6% in the third quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after acquiring an additional 3,268 shares during the last quarter. Finally, Neo Ivy Capital Management acquired a new position in Charles River Laboratories International during the third quarter worth about $966,000. 98.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CRL. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their price target for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their target price for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. Morgan Stanley lowered their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. UBS Group reissued a “neutral” rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, Bank of America lowered their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Hold” and an average price target of $189.77.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick bought 1,514 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the transaction, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James C. Foster bought 6,075 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Trading Down 3.2 %

Shares of CRL stock opened at $161.57 on Wednesday. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $273.32. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The stock has a market cap of $8.26 billion, a price-to-earnings ratio of 1,077.13, a PEG ratio of 4.54 and a beta of 1.45. The stock has a 50-day moving average of $165.32 and a 200-day moving average of $183.30.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the prior year, the business posted $2.46 earnings per share. The firm’s revenue was down 1.1% on a year-over-year basis. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).